Home/Pipeline/SomaDex

SomaDex

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

DexTech Medical

About DexTech Medical

DexTech Medical is a clinical-stage biotech developing targeted cancer therapies using its proprietary GuaDex platform, a carbohydrate-drug-conjugate technology. The company's pipeline includes several drug candidates, most notably OsteoDex for prostate cancer, which appears to be in advanced clinical studies. With a lean operational model, patented technology, and a focus on urological oncology, DexTech aims to address significant unmet medical needs in cancer treatment, though it faces the typical high-risk, high-cost challenges of drug development.

View full company profile

Therapeutic Areas

Oncology Urological Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active